tirzepatide sleep apnea study SURMOUNTs obstructive apnea, what's next in advancing GLP-1s? Tirzepatide in Obesity-Related Obstructive Sleep

The global, regional, and National patterns of change in the burden of nonmalignant upper Gastrointestinal diseases from 1990 to 2019 and the forecast for the next decade

PubMed evidence trail Research sources used to frame this page For Is Ozempic a Shot

In the same month, Rita announced that the second phase research data of retatrutide was released at the annual meeting of ADA, showing that at 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) reached the main endpoint of efficacy evaluation for obese or overweight participants without diabetes, with an average weight loss of 17.5%

Important: the results are promising, but this is still a medical treatment

Understanding the relationship between Zepbound and gallbladder issues, recognizing warning symptoms, and knowing when to seek medical attention are essential for safe and effective treatment